Insight Molecular Diagnostics (IMDX) Change in Cash (2015 - 2026)

Insight Molecular Diagnostics has disclosed Change in Cash across 12 years of filings, most recently posting $16.4 million for Q1 2026.

• Change in Cash for Q1 2026 came in at $16.4 million, down 26.6% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.4 million (down 113.26% YoY), and the FY2025 annual result was $2.6 million, up 424.5% from the prior year.
• Change in Cash came in at $16.4 million for Q1 2026 at Insight Molecular Diagnostics, up from -$7.3 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $24.4 million in Q2 2022 to a low of -$15.2 million in Q1 2022.
• The 5-year median for Change in Cash is -$4.4 million (2023), against an average of -$467647.1.
• Across the five-year window, Change in Cash slumped 304.27% in 2022 and surged 681.03% in 2025, its largest moves.
• Insight Molecular Diagnostics' Change in Cash stood at -$10.5 million in 2022, then soared by 58.76% to -$4.4 million in 2023, then jumped by 221.19% to $5.3 million in 2024, then tumbled by 238.27% to -$7.3 million in 2025, then jumped by 325.43% to $16.4 million in 2026.
• The last three Change in Cash figures came in at $16.4 million (Q1 2026), -$7.3 million (Q4 2025), and -$5.8 million (Q3 2025), per Business Quant data.